Lv2
170 积分 2023-05-17 加入
Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia
17天前
已完结
Plozasiran and Apolipoprotein C-III Inhibition
17天前
已完结
Apolipoprotein C-III inhibitors for the treatment of hypertriglyceridemia: a meta-analysis of randomized controlled trials
17天前
已完结
Population Pharmacokinetic Modeling of Subcutaneous Plozasiran in Healthy Volunteers and Patients with Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia, and Mixed Hyperlipidemia
17天前
已完结
Population Pharmacokinetic Modeling of Subcutaneous Plozasiran in Healthy Volunteers and Patients with Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia, and Mixed Hyperlipidemia
17天前
已完结
Efficacy and Safety of Apolipoprotein C‐ III Inhibitors in Hypertriglyceridemia: A Network Meta‐Analysis of Randomised Controlled Trials
17天前
已完结
Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia—Results of a Post Hoc Analysis of the Phase 3 PALISADE Study
17天前
已完结
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
24天前
已完结
Apolipoprotein C-III inhibitors for the treatment of hypertriglyceridemia: a meta-analysis of randomized controlled trials
1个月前
已完结
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
1个月前
已完结
皖公网安备34019202002308
